Skip to main content

Advertisement

SpringerLink
Log in

Gastrointestinal Motility Issues in Cancer Patients

  • GI Oncology (R Bresalier, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This paper seeks to highlight GI motility disorders that are frequently present in patients with a malignancy. GI dysmotility can occur due to the cancer itself or as a consequence of medical and surgical treatments. Often, symptoms are nonspecific and the diagnosis requires a high index of suspicion. The goal of the paper is to review the common motility problems seen in patients with cancer, their clinical manifestations, and options for management.

Recent Findings

Studies show that newer endoscopy techniques such as endoscopic mucosal dissection can cause esophageal dysmotility. Opioid-induced constipation is frequently encountered in patients with cancer.

Summary

Motility disorders in cancer patient can lead to clinical morbidity, poor quality of life, and malnutrition. Newer diagnostic tests and medical and surgical treatments may be helpful in improving the diagnosis and management of these disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Al-Shboul OA. The importance of interstitial cells of Cajal in the gastrointestinal tract. Saudi J Gastroenterol. 2013;19(1):3–15.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sanders KM, Koh SD, Ro S, Ward SM. Regulation of gastrointestinal motility--insights from smooth muscle biology. Nat Rev Gastroenterol Hepatol. 2012;9(11):633–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Hejazi RA, Zhang D, McCallum RW. Gastroparesis, pseudoachalasia and impaired intestinal motility as paraneoplastic manifestations of small cell lung cancer. Am J Med Sci. 2009;338(1):69–71.

    Article  PubMed  Google Scholar 

  4. •• DiBaise JK. Paraneoplastic gastrointestinal dysmotility: when to consider and how to diagnose. Gastroenterol Clin North Am. 2011;40(4):777–86. This paper gives a thorough description of the major paraneoplastic disorders that can cause GI dysmotility.

    Article  PubMed  Google Scholar 

  5. Grover M, Camilleri M. Treatment with methylnaltrexone and IVIG for paraneoplastic gastrointestinal dysmotility. Gastroenterol Hepatol (N Y). 2013;9(1):51–3.

    Google Scholar 

  6. Sadowski DC, Ackah F, Jiang B, Svenson LW. Achalasia: incidence, prevalence and survival. A population-based study. Neurogastroenterol Motil. 2010;22(9):e256–61.

    Article  PubMed  CAS  Google Scholar 

  7. Katzka DA, Farrugia G, Arora AS. Achalasia secondary to neoplasia: a disease with a changing differential diagnosis. Dis Esophagus. 2012;25(4):331–6.

    Article  PubMed  CAS  Google Scholar 

  8. Ponds FA, van Raath MI, Mohamed SMM, Smout A, Bredenoord AJ. Diagnostic features of malignancy-associated pseudoachalasia. Aliment Pharmacol Ther. 2017;45(11):1449–58.

    Article  PubMed  CAS  Google Scholar 

  9. Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol. 2013;108(8):1238–49 quiz 50.

    Article  PubMed  Google Scholar 

  10. • Hirano I, Pandolfino JE, Boeckxstaens GE. Functional lumen imaging probe for the management of esophageal disorders: expert review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol. 2017;15(3):325–34. This review gives a comprehensive overview of the use and indications of EndoFLIP to evaluate esophageal dysmotility.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ahuja NK, Agnihotri A, Lynch KL, Hoo-Fatt D, Onyimba F, McKnight M, et al. Esophageal distensibility measurement: impact on clinical management and procedure length. Dis Esophagus. 2017;30(8):1–8.

    Article  PubMed  CAS  Google Scholar 

  12. Noordzij IC, Curvers WL, Schoon EJ. Endoscopic resection for early esophageal carcinoma. J Thorac Dis. 2019;11(Suppl 5):S713–S22.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Bu BG, Linghu EQ, Li HK, Wang XX, Guo RB, Peng LH. Influence of endoscopic submucosal dissection on esophageal motility. World J Gastroenterol. 2013;19(29):4781–5.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Takahashi K, Sato Y, Takeuchi M, Sato H, Nakajima N, Ikarashi S, et al. Changes in esophageal motility after endoscopic submucosal dissection for superficial esophageal cancer: a high-resolution manometry study. Dis Esophagus. 2017;30(11):1–8.

    Article  PubMed  CAS  Google Scholar 

  15. Kuribayashi Y, Iizuka T, Nomura K, Furuhata T, Yamashita S, Matsui A, et al. Esophageal motility after extensive circumferential endoscopic submucosal dissection for superficial esophageal cancer. Digestion. 2018;98(3):153–60.

    Article  PubMed  Google Scholar 

  16. Takahashi K, Takeuchi M, Sato Y, Sato H, Mizuno K, Hashimoto S, et al. Evaluation of esophageal motility after endoscopic submucosal dissection for superficial esophageal cancer. Eur J Gastroenterol Hepatol. 2015;27(10):1187–92.

    Article  PubMed  Google Scholar 

  17. Huddy JR, Macharg FM, Lawn AM, Preston SR. Exocrine pancreatic insufficiency following esophagectomy. Dis Esophagus. 2013;26(6):594–7.

    Article  PubMed  CAS  Google Scholar 

  18. Mehran R, Rice D, El-Zein R, Huang JL, Vaporciyan A, Goodyear A, et al. Minimally invasive esophagectomy versus open esophagectomy, a symptom assessment study. Dis Esophagus. 2011;24(3):147–52.

    Article  PubMed  CAS  Google Scholar 

  19. Smith DS, Williams CS, Ferris CD. Diagnosis and treatment of chronic gastroparesis and chronic intestinal pseudo-obstruction. Gastroenterol Clin N Am. 2003;32(2):619–58.

    Article  Google Scholar 

  20. Antonoff MB, Puri V, Meyers BF, Baumgartner K, Bell JM, Broderick S, et al. Comparison of pyloric intervention strategies at the time of esophagectomy: is more better? Ann Thorac Surg. 2014;97(6):1950–7 discussion 657–8.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Fuchs HF, Broderick RC, Harnsberger CR, Divo FA, Coker AM, Jacobsen GR, et al. Intraoperative endoscopic Botox injection during total esophagectomy prevents the need for pyloromyotomy or dilatation. J Laparoendosc Adv Surg Tech A. 2016;26(6):433–8.

    Article  PubMed  Google Scholar 

  22. •• Zhang L, Hou SC, Miao JB, Lee H. Risk factors for delayed gastric emptying in patients undergoing esophagectomy without pyloric drainage. J Surg Res. 2017;213:46–50. This study highlights the risk factors that may predispose to delayed gastric emptying in patients undergoing esophagectomy.

    Article  PubMed  Google Scholar 

  23. Zhang T, Maclean J, Szczesniak M, Bertrand PP, Quon H, Tsang RK, et al. Esophageal dysmotility in patients following total laryngectomy. Otolaryngol Head Neck Surg. 2018;158(2):323–30.

    Article  PubMed  Google Scholar 

  24. Szczesniak MM, Maclean J, Zhang T, Graham PH, Cook IJ. Persistent dysphagia after head and neck radiotherapy: a common and under-reported complication with significant effect on non-cancer-related mortality. Clin Oncol (R Coll Radiol). 2014;26(11):697–703.

    Article  CAS  Google Scholar 

  25. Wu PI, Szczesniak MM, Maclean J, Choo L, Quon H, Graham PH, et al. Clinical utility of a functional lumen imaging probe in management of dysphagia following head and neck cancer therapies. Endoscopy. 2017;49(9):848–54.

    Article  PubMed  Google Scholar 

  26. Kinami S, Takahashi M, Urushihara T, Ikeda M, Yoshida M, Uenosono Y, et al. Background factors influencing postgastrectomy syndromes after various types of gastrectomy. World J Clin Cases. 2018;6(16):1111–20.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Tanizawa Y, Tanabe K, Kawahira H, Fujita J, Takiguchi N, Takahashi M, et al. Specific features of dumping syndrome after various types of gastrectomy as assessed by a newly developed integrated questionnaire, the PGSAS-45. Dig Surg. 2016;33(2):94–103.

    Article  PubMed  Google Scholar 

  28. van Beek AP, Emous M, Laville M, Tack J. Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management. Obes Rev. 2017;18(1):68–85.

    Article  PubMed  Google Scholar 

  29. Valderas JP, Ahuad J, Rubio L, Escalona M, Pollak F, Maiz A. Acarbose improves hypoglycaemia following gastric bypass surgery without increasing glucagon-like peptide 1 levels. Obes Surg. 2012;22(4):582–6.

    Article  PubMed  Google Scholar 

  30. Chiappetta S, Stier C. A case report: liraglutide as a novel treatment option in late dumping syndrome. Medicine (Baltimore). 2017;96(12):e6348.

    Article  Google Scholar 

  31. Shafi MA, Pasricha PJ. Post-surgical and obstructive gastroparesis. Curr Gastroenterol Rep. 2007;9(4):280–5.

    Article  PubMed  Google Scholar 

  32. Shah H, Wendorf G, Ahmed S, McElmurray L, Lahr C, Hughes M, et al. Treating an oft-unrecognized and troublesome entity: using gastric electrical stimulation to reduce symptoms of malignancy-associated gastroparesis. Support Care Cancer. 2017;25(1):27–31.

    Article  PubMed  Google Scholar 

  33. • Watanabe K, Hikichi T, Sato M, Nakamura J, Obara K, Ohira H. Change in gastric emptying eight weeks after endoscopic submucosal dissection in patients with early gastric cancer. Endosc Int Open. 2016;4(5):E597–602. This study highlights motility disturbances that can result after ESD treatment for gastric cancer.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Park YS, Shin DJ, Son SY, Kim KH, Park DJ, Ahn SH, et al. Roux stasis syndrome and gastric food stasis after laparoscopic distal gastrectomy with uncut Roux-en-Y reconstruction in gastric cancer patients: a propensity score matching analysis. World J Surg. 2018;42(12):4022–32.

    Article  PubMed  Google Scholar 

  35. Herbella FA, Silva LC, Vicentine FP, Patti MG. Roux-en-Y limb motility after total gastrectomy. J Gastrointest Surg. 2014;18(5):906–10.

    Article  PubMed  Google Scholar 

  36. Sorhaug S, Steinshamn SL, Waldum HL. Octreotide treatment for paraneoplastic intestinal pseudo-obstruction complicating SCLC. Lung Cancer. 2005;48(1):137–40.

    Article  PubMed  Google Scholar 

  37. Paik CN, Choi MG, Lim CH, Park JM, Chung WC, Lee KM, et al. The role of small intestinal bacterial overgrowth in postgastrectomy patients. Neurogastroenterol Motil. 2011;23(5):e191–6.

    Article  PubMed  CAS  Google Scholar 

  38. Deng L, Liu Y, Zhang D, Li Y, Xu L. Prevalence and treatment of small intestinal bacterial overgrowth in postoperative patients with colorectal cancer. Mol Clin Oncol. 2016;4(5):883–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. • Heneghan HM, Zaborowski A, Fanning M, McHugh A, Doyle S, Moore J, et al. Prospective study of malabsorption and malnutrition after esophageal and gastric cancer surgery. Ann Surg. 2015;262(5):803–7; discussion 7–8. This study evaluates the nutritional challenges in patients after surgery for esophageal and gastric cancer.

    Article  PubMed  Google Scholar 

  40. Liang S, Xu L, Zhang D, Wu Z. Effect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer. Turk J Gastroenterol. 2016;27(3):227–32.

    Article  PubMed  Google Scholar 

  41. Kumagai T, Rahman F, Smith AM. The microbiome and radiation induced-bowel injury: evidence for potential mechanistic role in disease pathogenesis. Nutrients. 2018;10(10).

    Article  PubMed Central  CAS  Google Scholar 

  42. Lacy BE, Weiser K. Gastrointestinal motility disorders: an update. Dig Dis. 2006;24(3–4):228–42.

    Article  PubMed  Google Scholar 

  43. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016.

  44. •• Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014;26(10):1386–95. This is a comprehensive overview of the prevalence and management of opioid-induced constipation.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387–96.

    Article  PubMed  CAS  Google Scholar 

  46. Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, et al. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2017;35(34):3859–66.

    Article  PubMed  CAS  Google Scholar 

  47. Ratuapli SK, Crowell MD, DiBaise JK, Vela MF, Ramirez FC, Burdick GE, et al. Opioid-induced esophageal dysfunction (OIED) in patients on chronic opioids. Am J Gastroenterol. 2015;110(7):979–84.

    Article  PubMed  CAS  Google Scholar 

  48. McQuade RM, Stojanovska V, Stavely R, Timpani C, Petersen AC, Abalo R, et al. Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15. Br J Pharmacol. 2018;175(4):656–77.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. McQuade RM, Stojanovska V, Bornstein JC, Nurgali K. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem. 2017;24(15):1537–57.

    Article  PubMed  CAS  Google Scholar 

  50. McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Front Pharmacol. 2016;7:414.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1466, Houston, TX, 77030, USA

    Mehnaz A. Shafi

Authors
  1. Mehnaz A. Shafi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehnaz A. Shafi.

Ethics declarations

Conflict of Interest

The author declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on GI Oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shafi, M.A. Gastrointestinal Motility Issues in Cancer Patients. Curr Gastroenterol Rep 21, 69 (2019). https://doi.org/10.1007/s11894-019-0738-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-019-0738-x

Keywords

Search

Navigation